切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2020, Vol. 08 ›› Issue (02) : 184 -188. doi: 10.3877/cma.j.issn.2095-5782.2020.02.017

所属专题: 文献

综述

球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的现状
周阳逸1, 顾建平1,(), 汪涛1   
  1. 1. 210006 江苏南京,南京医科大学附属南京医院介入科
  • 收稿日期:2020-04-16 出版日期:2020-05-25
  • 通信作者: 顾建平

Current status of balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension

Yangyi Zhou1, Jianping Gu1,(), Tao Wang1   

  1. 1. Department of Interventional Radiology, Affiliated Nanjing Hospital of Nanjing Medical University, Jiangsu Nanjing 210006, China
  • Received:2020-04-16 Published:2020-05-25
  • Corresponding author: Jianping Gu
  • About author:
    Corresponding author: Gu Jianping, Email:
引用本文:

周阳逸, 顾建平, 汪涛. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的现状[J]. 中华介入放射学电子杂志, 2020, 08(02): 184-188.

Yangyi Zhou, Jianping Gu, Tao Wang. Current status of balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2020, 08(02): 184-188.

慢性血栓栓塞性肺动脉高压被归类为第4类肺动脉高压。肺动脉内膜剥脱术是CTEPH的首选治疗。可溶性鸟苷酸环化酶刺激剂(利奥西呱)是首个被美国FDA批准用于治疗CTEPH的靶向药物,随着介入治疗的发展,经皮球囊肺动脉成形术逐渐成为无法行肺动脉内膜剥脱术、术后仍持续高压或复发患者的一种新选择。文章就经皮球囊肺动脉成形术发展过程、适应证、治疗流程及并发症作一综述。

Chronic thromboembolic pulmonary hypertension is classifed as Group-4 pulmonary hypertension caused by organized thrombi in pulmonary arteries. Pulmonary endarterectomy is the preferred treatment for CTEPH. The soluble guanylate cyclase stimulator (riociguat) is the sole FDA-licensed drug for the treatment of CTEPH. With the development of interventional therapy, balloon pulmonary angioplasty has gradually become new therapy for patients with inoperable CTEPH or residual or recurrent pulmonary hypertension following PEA. This article reviews the development process, indications, treatment procedures and complications of BPA to provide a better understanding and evaluation of BPA as a treatment option in CTEPH patients.

表1 近5年BPA用于CTEPH治疗的研究数据
[1]
Simonneau G, Gatzoulis M A, Adatia I, et al.Updated Clinical Classification of Pulmonary Hypertension[J]. Journal of the American College of Cardiology, 2013, 62(25): D34-D41.
[2]
Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data[J]. Chest, 1982, 81(2): 151-158.
[3]
Marion D, Irene L, Joanna Pep, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension clinical perspective[J]. Circulation, 2011, 124(18): 1973-1981.
[4]
Miniati M, Monti S, Bottai M , et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism[J]. Medicine, 2006, 85(5): 253-262.
[5]
Klok F A, Van Kralingen K W, Van Dijk A P J, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism[J]. Haematologica, 2010, 95(6): 970-975.
[6]
边竞,急性肺动脉栓塞后慢性血栓栓塞性肺动脉高压的发病率及危险因素分析[D].石家庄:河北医科大学,2015.
[7]
Piazza G, Goldhaber SZ. Current concepts: chronic thromboembolic pulmonary hypertension[J]. New England Journal of Medicine, 2011, 364(4): 351-360.
[8]
Jenkins D, Mayer E, Screaton N, et al. State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management[J]. European Respiratory Review, 2012, 21(123): 32-39.
[9]
Coulden, R. State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension[J]. Proceedings of the American Thoracic Society, 2006, 3(7):577-583.
[10]
Kim N H, Delcroix M, Jenkins D P, et al. Chronic thromboembolic pulmonary hypertension[J]. Journal of the American College of Cardiology, 2013, 62(25): 92-99.
[11]
Takayuki, Jujo-Sanada, Nobuhiro, et al. The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study[J]. Pulmonary Circulation, 2017,7(3):684-691.
[12]
Romaszkiewicz R, Lewczuk J, Piszko P, et al. Results of one-year anticoagulation in patients with newly detected chronic thromboembolic pulmonary hypertension not treated with pulmonary endarterectomy[J]. Kardiologia Polska, 2006, 64(11): 1196-1202.
[13]
刘盛.慢性血栓栓塞性肺动脉高压的外科治疗[J].临床外科杂志,2017, 25(5): 331-334.
[14]
Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH) results from an international prospective registry[J]. Circulation, 2011, 124(18): 1973-1981.
[15]
Fukuda K, Date H, Doi S. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017)[J]. Circulation Journal, 2019, 83(4): 842-945.
[16]
Yamada N. Percutaneous transluminal pulmonary angioplasty for distal-type chronic thromboembolic pulmonary hypertension[J]. Circulation Journal, 2012, 76(2): 307-308.
[17]
Gentles TL, Lock JE, Perry SB, et al. High pressure balloon angioplasty for branch pulmonary artery stenosis: early experience[J]. Journal of the American College of Cardiology, 1993, 22(3): 867-872.
[18]
Voorburg J AI, Cats VM, Buis B, et al. Balloon angioplasty in the treatment of pulmonary hypertension caused by pulmonary embolism[J]. Chest, 1988, 94(6): 1249-1253.
[19]
Feinstein J A, Goldhaber S Z, Lock J E, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension[J]. Circulation, 2001, 103(1): 10-13.
[20]
Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension[J]. Circulation Cardiovascular Interventions, 2012, 5(6): 748-755.
[21]
Inami T, Kataoka M, Ishiguro H, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty[J]. Cardiovascular Interventions, 2013, 6(7): 725-736.
[22]
Taniguchi Y, Miyagawa K, Nakayama K, et al. Balloon pulmonary angioplasty: An additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension[J]. EuroIntervention, 2014, 10(4): 518-525.
[23]
Wang W, Wen L, Song Z, et al. Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis[J]. Clin Cardiol, 2019. 42(8): 741-752.
[24]
Tatebe S, Sugimura K, Aoki T, et al. Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension[J]. Circulation Journal, 2016, 80(4): 980-988.
[25]
Ogo T, Fukuda T, Tsuji A, et al. Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography[J]. European Journal of Radiology, 2017, 89: 270-276.
[26]
Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry[J]. Cir Cardiovasc Qual Outcomes, 2017, 10(11): e004029.
[27]
Kwon W, Yang JH, Park TK, et al. Impact of balloon pulmonary angioplasty on hemodynamics and clinical outcomes in patients with chronic thromboembolic pulmonary hypertension: the initial korean experience[J]. J Korean Med Sci,2018,33(4):e24.
[28]
van Thor MCJ, Lely RJ, Braams NJ, et al. Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands[J]. Neth Heart J, 2020. 28(2): 81-88.
[29]
Hoole SP, Coghlan JG, Cannon JE, et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience[J]. Open Heart, 2020, 7(1): e001144.
[30]
Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated recommendations from the Cologne Consensus Conference 2018[J]. Int J Cardiol, 2018, 272S: 69-78.
[31]
Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)[J]. European Heart Journal, 2015, 37(1): 67-119.
[32]
Lau, EMT, Tamura Y, McGoon MD, et al. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress[J]. European Respiratory Journal, 2015,46(4): 879-882.
[33]
Lang I, Meyer BC, Ogo T, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension[J]. European Respiratory Review, 2017, 26(143): 160-119.
[34]
Moriarty, JM, Khan SN, Kao SD, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Cardiovasc Intervent Radiol, 2018, 41(12): 1826-1839.
[35]
Mahmud E, Behnamfar O, Ang L, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Interv Cardiol Clin, 2018, 7(1): 103-117.
[36]
Ikeda N. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Cardiovasc Interv Ther, 2020, 35(2): 130-141.
[37]
Sugiyama MT, Fukuda Y, Sanda Y, et al. Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension; imaging with cone beam computed tomography[J]. Japanese Journal of Radiology, 2014, 32(7):375-382.
[38]
Kawakami T, Ogawa A, Miyaji K, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty[J]. Circulation Cardiovascular Interventions, 2016, 9(10): e003318.
[39]
Tatebe S, Fukumoto Y, Sugimura K, et al. Optical coherence tomography as a novel diagnostic tool for distal type chronic thromboembolic pulmonary hypertension[J]. Circulation Journal, 2010, 74(8): 1742-1744.
[40]
Ishiguro H, Kataoka M, Inami T, et al. Percutaneous transluminal pulmonary angioplasty for central-type chronic thromboembolic pulmonary hypertension[J]. Jacc Cardiovascular Interventions, 2013, 6(11): 1212-1213.
[41]
Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension[J]. Indian Heart Journal, 2012, 65(3): 349-350.
[42]
Moriyama K, Satoh T, Motoyasu A, et al. High-flow nasal cannula therapy in a patient with reperfusion pulmonary edema following percutaneous transluminal pulmonary angioplasty[J]. Case Reports in Pulmonology, 2014. DOI: 10.1155/2014/837612.
[43]
Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Heart, 2013, 99(19): 1415-1420.
[1] 肖俊, 李浩, 孔令泉, 厉红元, 吴凯南. 乳腺癌术后肺栓塞一例并文献复习[J]. 中华乳腺病杂志(电子版), 2021, 15(01): 58-59.
[2] 王娜, 褚娇娇, 张鹏, 夏岑峰. 血栓调节蛋白基因多态性与肺栓塞的风险评估[J]. 中华危重症医学杂志(电子版), 2021, 14(04): 269-274.
[3] 张帅, 袁媛, 邢振川, 王焕勇, 张虹霞. 71例急性肺血栓栓塞症并发肺梗死临床特征[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 566-568.
[4] 胡宗俊, 陈建国, 黄霞. ARDS机械通气继发肺栓塞危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 388-390.
[5] 郭亮, 何思毅, 杨毓斌, 关尚全, 吴学玲, 李少莹. 高原肺水肿患者临床特点分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 879-881.
[6] 张立夏, 高泽宾, 庞停, 张越群. 银杏叶提取物联合尿激酶治疗急性肺栓塞的疗效及对CYS-C、NT-ProBNP、TnI与D-D的影响[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 733-735.
[7] 尹婷婷, 刘基, 王康, 陈忠. CT肺动脉阻塞指数与血清D-二聚体、PLR水平的相关性分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 521-523.
[8] 欧敏, 王斌, 张明周, 董俊康, 刘禹, 廖品亮, 任合玲, 姜欣, 蔡晓莲. 心电图及心脏超声在急性肺栓塞诊断及危险分层中的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 502-505.
[9] 雷丽均, 赵才林, 徐静. 急性肺栓塞的研究进展[J]. 中华肺部疾病杂志(电子版), 2022, 15(01): 127-128.
[10] 宗海娟, 张蓉蓉, 卢坤琴. 慢性阻塞性肺疾病继发肺栓塞的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(01): 58-60.
[11] 周莹, 刘洋, 阳韬, 王剑. 老年肺癌患者合并肺栓塞的危险因素及Khorana评分预测意义[J]. 中华肺部疾病杂志(电子版), 2021, 14(05): 675-676.
[12] 马继韬, 唐明星, 蒙旭, 王胤佳. 产后大出血早期并发肺栓塞一例[J]. 中华重症医学电子杂志, 2021, 07(04): 372-375.
[13] 王金志, 陶新曹, 谢万木, 傅志辉, 赵蕴伟, 黄强, 翟振国. 球囊肺动脉成形术在慢性血栓栓塞性肺动脉高压治疗中的进展[J]. 中华介入放射学电子杂志, 2023, 11(03): 262-267.
[14] 史亚东, 顾建平. 无症状肺栓塞的诊断与治疗进展[J]. 中华介入放射学电子杂志, 2023, 11(02): 155-158.
[15] 卢光东, 贾振宇, 张金星, 赵林波, 施海彬. 大鼠急性肺栓塞模型的建立及CD147表达水平对栓塞大鼠肺动脉压力变化的影响[J]. 中华介入放射学电子杂志, 2021, 09(03): 313-318.
阅读次数
全文


摘要